Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP1 and amylin analogues owenhaskins Dec 19, 2025 2 min read Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition
Interestingly, transient type I IFN gene expression in peripheral blood is a suggested risk factor preceding autoantibody seroconversion and autoimmunity in children with a genetic predisposition to T1D, though not all children progress to the disease (116, 117)
You can find out more about the impact of the UKs B12 crisis and why early detection is so important
Chimienti, F., Devergnas, S., Favier, A
Patient satisfaction data from telehealth platforms has been positive, and a growing body of retrospective evidence supports efficacy
Carefully follow the steps below